Gaël Roth, MD, PhD, is Professor of GI Oncology at Université Grenoble Alpes and a senior clinician at CHU Grenoble Alpes, France, specializing in advanced hepato-biliary and pancreatic cancers. His research focuses on overcoming chemotherapy resistance through novel targeted and translational approaches. He served as principal coordinator of the LAPNET-1 trial, testing an anti-netrin1 in combination with mFOLFIRINOX (Nature 2026), and leads ACAPELLA, the first European study evaluating alpha-emitting radioactive micro-rods delivered via endoscopic ultrasound, both in locally advanced pancreatic ductal adenocarcinoma. Among other clinical trials, he leads also AMPIRINOX randomized phase 3 trial in resected ampullary carcinomas, and PEHRICCA phase 2 trial in resectable intrahepatic cholangiocarcinoma. He is an active member of multiple national and international scientific groups and societies around pancreatobiliary cancers research and serves as President of ACABi, the French association for biliary tract cancers.